Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $5.5 million.

  • Taysha Gene Therapies' Current Deferred Revenue fell 5338.98% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 5338.98%. This contributed to the annual value of $9.8 million for FY2024, which is 4587.43% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' Current Deferred Revenue stood at $5.5 million, which was down 5338.98% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Current Deferred Revenue ranged from a high of $33.6 million in Q4 2022 and a low of $5.5 million during Q2 2025
  • For the 4-year period, Taysha Gene Therapies' Current Deferred Revenue averaged around $15.7 million, with its median value being $14.2 million (2024).
  • Per our database at Business Quant, Taysha Gene Therapies' Current Deferred Revenue plummeted by 3281.63% in 2024 and then plummeted by 5955.88% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Current Deferred Revenue stood at $33.6 million in 2022, then plummeted by 46.04% to $18.1 million in 2023, then crashed by 45.87% to $9.8 million in 2024, then plummeted by 43.88% to $5.5 million in 2025.
  • Its Current Deferred Revenue was $5.5 million in Q3 2025, compared to $5.5 million in Q2 2025 and $7.5 million in Q1 2025.